Showing results (61-70 of 276) with videos related to
Sort By:
Pageof 28
British Journal of Cancer|December 1, 1992
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexesS Y Loh, P Mistry, L R Kelland, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1990
The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugsK R Harrap, M Jones, J Siracky, et al.Journal of Chromatography|February 7, 1992
Rapid and selective isolation of radiolabelled inositol phosphates from cancer cells using solid-phase extractionL Anderson, J Cummings, J F SmythBiochemical Pharmacology|April 20, 1994
Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of actionJ Cummings, L Allan, J F SmythAnalytical Biochemistry|April 1, 1991
Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductaseJ Cummings, A Bartoszek, J F SmythCancer Chemotherapy and Pharmacology|January 1, 1996
cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell linesM G Ormerod, C O'Neill, D Robertson, et al.Cancer Chemotherapy and Pharmacology|January 1, 1996
Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120M I Walton, P Goddard, L R Kelland, et al.Cancer Chemotherapy and Pharmacology|January 1, 1992
Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discoveryL R Kelland, M Jones, G Abel, et al.Cancer Chemotherapy and Pharmacology|January 1, 1990
The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing miceP M Goddard, M Jones, L A Pollard, et al.Thorax|May 1, 1986
Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinomaR J Fergusson, J Carmichael, J F SmythPageof 28